Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?
Journal
Nature reviews. Neurology
ISSN: 1759-4766
Titre abrégé: Nat Rev Neurol
Pays: England
ID NLM: 101500072
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
23
12
2021
pubmed:
11
2
2022
medline:
22
4
2022
entrez:
10
2
2022
Statut:
ppublish
Résumé
One in three people will be diagnosed with cancer during their lifetime. The community of cancer patients is growing, and several common cancers are becoming increasingly chronic; thus, cancer survivorship is an important part of health care. A large body of research indicates that cancer and cancer therapies are associated with cognitive impairment. This research has mainly concentrated on chemotherapy-associated cognitive impairment but, with the arrival of immunotherapies, the focus is expected to widen and the number of studies investigating the potential cognitive effects of these new therapies is rising. Meanwhile, patients with cognitive impairment and their healthcare providers are eagerly awaiting effective approaches to intervene against the cognitive effects of cancer treatment. In this Review, we take stock of the progress that has been made and discuss the steps that need to be taken to accelerate research into the biology underlying cognitive decline following chemotherapy and immunotherapy and to develop restorative and preventive interventions. We also provide recommendations to clinicians on how to best help patients who are currently experiencing cognitive impairment.
Identifiants
pubmed: 35140379
doi: 10.1038/s41582-021-00617-2
pii: 10.1038/s41582-021-00617-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-185Informations de copyright
© 2022. Springer Nature Limited.
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338
Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. 69, 363–385 (2019).
pubmed: 31184787
Mayo, S. J. et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support. Care Cancer 29, 2821–2840 (2020).
pubmed: 33231809
Schagen, S. B. et al. Monitoring and optimising cognitive function in cancer patients: present knowledge and future directions. EJC Suppl. 12, 29–40 (2014).
pubmed: 26217164
pmcid: 4250534
Noll, K. R. et al. Monitoring of neurocognitive function in the care of patients with brain tumors. Curr. Treat. Options Neurol. 21, 33 (2019).
pubmed: 31250277
Matsos, A. & Johnston, I. N. Chemotherapy-induced cognitive impairments: a systematic review of the animal literature. Neurosci. Biobehav. Rev. 102, 382–399 (2019). A systematic evaluation of cognitive domains and underlying neural mechanisms disrupted by chemotherapy of various classes.
pubmed: 31063740
Deprez, S. et al. International cognition and cancer task force recommendations for neuroimaging methods in the study of cognitive impairment in non-CNS cancer patients. J. Natl. Cancer Inst. 110, 223–231 (2018). Recommendations for MRI sequences to facilitate increased use of neuroimaging in studies on cancer and cognition.
pubmed: 29365201
pmcid: 6658857
Gibson, E. M. & Monje, M. Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment. Curr. Opin. Oncol. 31, 531–539 (2019).
pubmed: 31449084
pmcid: 7205182
Gibson, E. M. & Monje, M. Microglia in cancer therapy-related cognitive impairment. Trends Neurosci. 44, 441–451 (2021).
pubmed: 33674135
Ahles, T. A., Root, J. C. & Ryan, E. L. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J. Clin. Oncol. 30, 3675–3686 (2012).
pubmed: 23008308
pmcid: 3675678
Wefel, J. S. et al. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology 23, 626–633 (2014).
pubmed: 24339329
Correa, D. D. et al. Cognitive functions in long-term survivors of ovarian cancer. Gynecol. Oncol. 119, 366–369 (2010).
pubmed: 20630576
Gonzalez, B. D. et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J. Clin. Oncol. 33, 2021–2027 (2015).
pubmed: 25964245
pmcid: 4461804
Cruzado, J. A. et al. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support. Care Cancer 22, 1815–1823 (2014).
pubmed: 24535240
Underwood, E. A. et al. Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Res. Treat. 168, 299–310 (2018).
pubmed: 29264751
Touat, M., Talmasov, D., Ricard, D. & Psimaras, D. Neurological toxicities associated with immune-checkpoint inhibitors. Curr. Opin. Neurol. 30, 659–668 (2017).
pubmed: 28938341
Bartels, F. et al. Neuronal autoantibodies associated with cognitive impairment in melanoma patients. Ann. Oncol. 30, 823–829 (2019). Among the first reports on neuronal auto-antibodies as possible biomarkers in the development of cancer-related cognitive impairment.
pubmed: 30840061
pmcid: 6551450
Ruark, J. et al. Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy. Biol. Blood Marrow Transpl. 26, 34–43 (2020).
Olson, B. & Marks, D. L. Pretreatment cancer-related cognitive impairment-mechanisms and outlook. Cancers 11, 687 (2019).
pmcid: 6562730
van der Willik, K. D. et al. Trajectories of cognitive function prior to cancer diagnosis: a population-based study. J. Natl. Cancer Inst. 112, 480–488 (2020).
pubmed: 31498410
DeVita, V. T. Jr & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643–8653 (2008).
pubmed: 18974103
Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623–1649 (2020).
pubmed: 32979513
Hanna, N. H. et al. Therapy for Stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J. Clin. Oncol. 38, 1608–1632 (2020).
pubmed: 31990617
DeSantis, C. E. et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 64, 252–271 (2014).
pubmed: 24890451
Andre, F. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx. J. Clin. Oncol. 37, 1956–1964 (2019).
pubmed: 31150316
Kris, M. G. et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J. Clin. Oncol. 35, 2960–2974 (2017).
pubmed: 28437162
Dietrich, J., Han, R., Yang, Y., Mayer-Pröschel, M. & Noble, M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol. 5, 22 (2006).
pubmed: 17125495
pmcid: 2000477
Delou, J. M. A., Souza, A. S. O., Souza, L. C. M. & Borges, H. L. Highlights in resistance mechanism pathways for combination therapy. Cells 8, 1013 (2019).
pmcid: 6770082
Lange, M. et al. Baseline cognitive functions among elderly patients with localised breast cancer. Eur. J. Cancer 50, 2181–2189 (2014).
pubmed: 24958735
Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N. & Meyers, C. A. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100, 2292–2299 (2004).
pubmed: 15160331
Wefel, J. S., Saleeba, A. K., Buzdar, A. U. & Meyers, C. A. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116, 3348–3356 (2010).
pubmed: 20564075
Wefel, J. S., Kesler, S. R., Noll, K. R. & Schagen, S. B. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J. Clin. 65, 123–138 (2015).
pubmed: 25483452
Janelsins, M. C. et al. Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study. J. Clin. Oncol. 36, Jco2018786624 (2018).
Koppelmans, V. et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J. Clin. Oncol. 30, 1080–1086 (2012). One of the few studies on very late cognitive effects of chemotherapy.
pubmed: 22370315
Wefel, J. S. & Schagen, S. B. Chemotherapy-related cognitive dysfunction. Curr. Neurol. Neurosci. Rep. 12, 267–275 (2012).
pubmed: 22453825
Boykoff, N., Moieni, M. & Subramanian, S. K. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J. Cancer Surviv. 3, 223–232 (2009).
pubmed: 19760150
pmcid: 2775113
Von Ah, D. et al. Cancer, cognitive impairment, and work-related outcomes: an integrative review. Oncol. Nurs. Forum 43, 602–616 (2016).
pubmed: 27541553
van Dam, F. S. et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J. Natl Cancer Inst. 90, 210–218 (1998).
pubmed: 9462678
Schagen, S. B., Hamburger, H. L., Muller, M. J., Boogerd, W. & van Dam, F. S. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J. Neurooncol. 51, 159–165 (2001).
pubmed: 11386413
Stouten-Kemperman, M. M. et al. Neurotoxicity in breast cancer survivors ≥10 years post-treatment is dependent on treatment type. Brain Imaging Behav. 9, 275–284 (2015).
pubmed: 24858488
Collins, B., MacKenzie, J., Tasca, G. A., Scherling, C. & Smith, A. Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology 22, 1517–1527 (2013). The first and only study that evaluated cognition after each course of chemotherapy.
pubmed: 22936651
Hutchinson, A. D., Hosking, J. R., Kichenadasse, G., Mattiske, J. K. & Wilson, C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat. Rev. 38, 926–934 (2012).
pubmed: 22658913
Gutenkunst, S. L., Vardy, J. L., Dhillon, H. M. & Bell, M. L. Correlates of cognitive impairment in adult cancer survivors who have received chemotherapy and report cognitive problems. Support. Care Cancer 29, 1377–1386 (2021).
pubmed: 32666213
Boscher, C. et al. Perceived cognitive impairment in breast cancer survivors and its relationships with psychological factors. Cancers 12, 3000 (2020).
pmcid: 7602817
Li, M. & Caeyenberghs, K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci. Biobehav. Rev. 92, 304–317 (2018).
pubmed: 29791867
de Ruiter, M. B. et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum. Brain Mapp. 33, 2971–2983 (2012).
pubmed: 22095746
Deprez, S. et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum. Brain Mapp. 32, 480–493 (2011).
pubmed: 20725909
Kesler, S. R. et al. Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc. Natl Acad. Sci. USA 110, 11600–11605 (2013).
pubmed: 23798392
pmcid: 3710809
Miao, H. et al. Functional connectivity change of brain default mode network in breast cancer patients after chemotherapy. Neuroradiology 58, 921–928 (2016).
pubmed: 27278455
Zhang, Y. et al. Chemotherapy-induced functional changes of the default mode network in patients with lung cancer. Brain Imaging Behav. 14, 847–856 (2020).
pubmed: 30617783
Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L. & Mak, T. W. Beyond immune checkpoint blockade: emerging immunological strategies. Nat. Rev. Drug Discov. 20, 899–919 (2021).
pubmed: 33686237
Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
pubmed: 25605845
pmcid: 4980573
Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
pubmed: 23724867
pmcid: 5698004
Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948–960 (2019).
pubmed: 31160251
Zimmer, L. et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 395, 1558–1568 (2020).
pubmed: 32416781
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
pubmed: 29658856
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
pubmed: 29562145
pmcid: 5972549
Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).
pubmed: 28967485
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
pubmed: 29320654
Maus, M. V. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J. Immunother. Cancer 8, e001511 (2020).
pubmed: 33335028
pmcid: 7745688
Cuzzubbo, S. et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer 73, 1–8 (2017).
pubmed: 28064139
McGinnis, G. J. et al. Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget 8, 9155–9173 (2017).
pubmed: 27893434
Rogiers, A. et al. Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study. Support. Care Cancer 28, 3267–3278 (2020). One of the first studies on the potential cognitive effects of immunotherapy.
pubmed: 31745697
Rogiers, A. et al. Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab. J. Immunol. Res. 2020, 2192480 (2020).
pubmed: 32775464
pmcid: 7391091
Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 34, 45–55 (2019).
pubmed: 30528964
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
pubmed: 29226797
pmcid: 5882485
Park, J. H. et al. Long-Term Follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018).
pubmed: 29385376
pmcid: 6637939
Patterson, J. D., Henson, J. C., Breese, R. O., Bielamowicz, K. J. & Rodriguez, A. CAR T cell therapy for pediatric brain tumors. Front. Oncol. 10, 1582 (2020).
pubmed: 32903405
pmcid: 7435009
Neelapu, S. S. Managing the toxicities of CAR T-cell therapy. Hematol. Oncol. 37 (Suppl. 1), 48–52 (2019).
pubmed: 31187535
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).
pubmed: 24876563
pmcid: 4093680
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625–638 (2019).
Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov. 7, 1404–1419 (2017).
pubmed: 29025771
pmcid: 5718945
Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958–971 (2018).
pubmed: 29880584
pmcid: 6385599
Shalabi, H. et al. Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat. Rev. Clin. Oncol. 18, 363–378 (2021).
pubmed: 33495553
pmcid: 8335746
Belin, C. et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci. Rep. 10, 18997 (2020).
pubmed: 33149178
pmcid: 7642402
Amidi, A. et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav. 11, 769–783 (2017).
pubmed: 27240852
Small, B. J. et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 117, 1369–1376 (2011).
pubmed: 21425136
Buskbjerg, C. D. R., Amidi, A., Demontis, D., Nissen, E. R. & Zachariae, R. Genetic risk factors for cancer-related cognitive impairment: a systematic review. Acta Oncol. 58, 537–547 (2019).
pubmed: 30822178
Sharafeldin, N. et al. Clinical and genetic risk prediction of cognitive impairment after blood or marrow transplantation for hematologic malignancy. J. Clin. Oncol. 38, 1312–1321 (2020).
pubmed: 32083992
pmcid: 8265387
Vega, J. N., Dumas, J. & Newhouse, P. A. Cognitive effects of chemotherapy and cancer-related treatments in older adults. Am. J. Geriatr. Psychiatry 25, 1415–1426 (2017).
pubmed: 28495470
pmcid: 5630507
Fernandez, H. R., Varma, A., Flowers, S. A. & Rebeck, G. W. Cancer chemotherapy related cognitive impairment and the impact of the Alzheimer’s disease risk factor APOE. Cancers 12, 3842 (2020).
pmcid: 7766535
Moruno Manchon, J. F. et al. Levetiracetam mitigates doxorubicin-induced DNA and synaptic damage in neurons. Sci. Rep. 6, 25705 (2016).
Torre, M., Dey, A., Woods, J. K. & Feany, M. B. Elevated oxidative stress and DNA damage in cortical neurons of chemotherapy patients. J. Neuropathol. Exp. Neurol. 80, 705–712 (2021).
pubmed: 34363676
pmcid: 8660580
Makarevich, O. et al. Mithramycin selectively attenuates DNA-damage-induced neuronal cell death. Cell Death Dis. 11, 587 (2020).
pubmed: 32719328
pmcid: 7385624
Alhareeri, A. A. et al. Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study. Breast Cancer Res. 22, 137 (2020).
pubmed: 33276807
pmcid: 7716505
Moruno-Manchon, J. F. et al. TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin. Aging 8, 3507–3519 (2016).
pubmed: 27992857
pmcid: 5270683
Wardill, H. R. et al. Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction. Int. J. Cancer 139, 2635–2645 (2016).
pubmed: 27367824
von Kobbe, C. Targeting senescent cells: approaches, opportunities, challenges. Aging 11, 12844–12861 (2019). Introduction to cellular senescence in the treatment of ageing-related diseases, including cancer-related cognitive impairment.
Mignone, R. G. & Weber, E. T. Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA. Brain Res. 1111, 26–29 (2006).
pubmed: 16879810
Seigers, R. et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav. Brain Res. 186, 168–175 (2008).
pubmed: 17854921
Licht, T. et al. Hippocampal neural stem cells facilitate access from circulation via apical cytoplasmic processes. eLife 9, e52134 (2020).
pubmed: 32496193
pmcid: 7297534
Monje, M. L. et al. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann. Neurol. 62, 515–520 (2007).
pubmed: 17786983
Subramaniam, C. B. et al. The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment. Neurosci. Biobehav. Rev. 116, 470–479 (2020).
pubmed: 32681936
Andres, A. L., Gong, X., Di, K. & Bota, D. A. Low-doses of cisplatin injure hippocampal synapses: a mechanism for ‘chemo’ brain? Exp. Neurol. 255, 137–144 (2014).
pubmed: 24594220
pmcid: 4059602
Chiang, A. C. A., Huo, X., Kavelaars, A. & Heijnen, C. J. Chemotherapy accelerates age-related development of tauopathy and results in loss of synaptic integrity and cognitive impairment. Brain Behav. Immun. 79, 319–325 (2019).
pubmed: 30953771
pmcid: 6591052
Liu, R. Y., Zhang, Y., Coughlin, B. L., Cleary, L. J. & Byrne, J. H. Doxorubicin attenuates serotonin-induced long-term synaptic facilitation by phosphorylation of p38 mitogen-activated protein kinase. J. Neurosci. 34, 13289–13300 (2014).
pubmed: 25274809
pmcid: 4180468
Huo, X., Reyes, T. M., Heijnen, C. J. & Kavelaars, A. Cisplatin treatment induces attention deficits and impairs synaptic integrity in the prefrontal cortex in mice. Sci. Rep. 8, 17400 (2018).
pubmed: 30479361
pmcid: 6258730
Cole, P. D. et al. Memantine protects rats treated with intrathecal methotrexate from developing spatial memory deficits. Clin. Cancer Res. 19, 4446–4454 (2013).
pubmed: 23833301
pmcid: 4169109
Vijayanathan, V., Gulinello, M., Ali, N. & Cole, P. D. Persistent cognitive deficits, induced by intrathecal methotrexate, are associated with elevated CSF concentrations of excitotoxic glutamate analogs and can be reversed by an NMDA antagonist. Behav. Brain Res. 225, 491–497 (2011).
pubmed: 21856332
Karschnia, P., Parsons, M. W. & Dietrich, J. Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol. 20, e92–e102 (2019).
pubmed: 30723041
Li, G. M. Mechanisms and functions of DNA mismatch repair. Cell Res. 18, 85–98 (2008).
pubmed: 18157157
Zell, J., Rota Sperti, F., Britton, S. & Monchaud, D. DNA folds threaten genetic stability and can be leveraged for chemotherapy. RSC Chem. Biol. 2, 47–76 (2021).
pubmed: 35340894
Maynard, S., Fang, E. F., Scheibye-Knudsen, M., Croteau, D. L. & Bohr, V. A. DNA damage, DNA repair, aging, and neurodegeneration. Cold Spring Harb. Perspect. Med. 5, a025130 (2015).
pubmed: 26385091
pmcid: 4588127
Madabhushi, R., Pan, L. & Tsai, L. H. DNA damage and its links to neurodegeneration. Neuron 83, 266–282 (2014).
pubmed: 25033177
pmcid: 5564444
Bagnall-Moreau, C., Chaudhry, S., Salas-Ramirez, K., Ahles, T. & Hubbard, K. Chemotherapy-induced cognitive impairment is associated with increased inflammation and oxidative damage in the hippocampus. Mol. Neurobiol. 56, 7159–7172 (2019).
pubmed: 30989632
pmcid: 6728167
Heck, J. E., Albert, S. M., Franco, R. & Gorin, S. S. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J. Am. Geriatr. Soc. 56, 1687–1692 (2008).
pubmed: 18691280
Wyld, L. et al. Senescence and cancer: a review of clinical implications of senescence and senotherapies. Cancers 12, 2134 (2020).
pmcid: 7464619
Yang, H. et al. The role of cellular reactive oxygen species in cancer chemotherapy. J. Exp. Clin. Cancer Res. 37, 266 (2018).
pubmed: 30382874
pmcid: 6211502
Dominic, A., Hamilton, D. & Abe, J. I. Mitochondria and chronic effects of cancer therapeutics: the clinical implications. J. Thromb. Thrombolysis 51, 884–889 (2020).
pubmed: 33079380
pmcid: 8055726
Moruno-Manchon, J. F. et al. Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Mol. Cell. Neurosci. 86, 65–71 (2018).
pubmed: 29180229
Golubev, A., Hanson, A. D. & Gladyshev, V. N. A tale of two concepts: harmonizing the free radical and antagonistic pleiotropy theories of aging. Antioxid. Redox Signal. 29, 1003–1017 (2018).
pubmed: 28874059
pmcid: 6104246
Gaman, A. M., Uzoni, A., Popa-Wagner, A., Andrei, A. & Petcu, E. B. The role of oxidative stress in etiopathogenesis of chemotherapy induced cognitive impairment (CICI)-“Chemobrain”. Aging Dis. 7, 307–317 (2016).
pubmed: 27330845
pmcid: 4898927
Gong, S. et al. Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice. J. Transl. Med. 19, 147 (2021).
pubmed: 33849559
pmcid: 8045234
Konsman, J. P. et al. Translationally relevant mouse model of early life cancer and chemotherapy exposure results in brain and small intestine cytokine responses: a potential link to cognitive deficits. Brain Behav. Immun. 99, 192–202 (2021).
pubmed: 34655730
Gibson, E. M. et al. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell 176, 43–55.e13 (2019). Thorough evaluation of mechanisms underlying chemotherapy-induced cognitive impairment.
pubmed: 30528430
Wang, B. et al. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma. J. Exp. Clin. Cancer Res. 39, 170 (2020).
pubmed: 32854746
pmcid: 7450600
Montagne A. et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296–302 (2015).
pubmed: 25611508
pmcid: 4350773
Bauer, M. et al. Impaired clearance from the brain increases the brain exposure to metoclopramide in elderly subjects. Clin. Pharmacol. Ther. 109, 754–761 (2021).
pubmed: 32966590
Pluvinage, J. V. & Wyss-Coray, T. Systemic factors as mediators of brain homeostasis, ageing and neurodegeneration. Nat. Rev. Neurosci. 21, 93–102 (2020).
pubmed: 31913356
Villeda, S. A. et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90–94 (2011).
pubmed: 21886162
pmcid: 3170097
Williams, A. M. et al. Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J. Neuroimmunol. 314, 17–23 (2018).
pubmed: 29128118
Carneiro-Filho, B. A. et al. Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig. Dis. Sci. 49, 65–72 (2004).
pubmed: 14992437
Honarpisheh, P. & McCullough, L. D. Sex as a biological variable in the pathology and pharmacology of neurodegenerative and neurovascular diseases. Br. J. Pharmacol. 176, 4173–4192 (2019).
pubmed: 30950038
pmcid: 6877795
Griesbeck, M. et al. Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women. J. Immunol. 195, 5327–5336 (2015).
pubmed: 26519527
pmcid: 4654231
Battram, A. M., Bachiller, M. & Martín-Antonio, B. Senescence in the development and response to cancer with immunotherapy: a double-edged sword. Int. J. Mol. Sci. 21, 4346 (2020).
pmcid: 7352478
Wang, B., Kohli, J. & Demaria, M. Senescent cells in cancer therapy: friends or foes? Trends Cancer 6, 838–857 (2020).
pubmed: 32482536
Csipo, T., Lipecz, A., Ashpole, N. M., Balasubramanian, P. & Tarantini, S. Astrocyte senescence contributes to cognitive decline. Geroscience 42, 51–55 (2020).
pubmed: 31773453
Kapasi, A. & Schneider, J. A. Vascular contributions to cognitive impairment, clinical Alzheimer’s disease, and dementia in older persons. Biochim. Biophys. Acta 1862, 878–886 (2016).
pubmed: 26769363
Koh, Y. Q. et al. Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21, 2755 (2020).
pmcid: 7215650
Goldberg, S. B. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976–983 (2016).
pubmed: 27267608
pmcid: 5526047
Yshii, L. M., Hohlfeld, R. & Liblau, R. S. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat. Rev. Neurol. 13, 755–763 (2017).
pubmed: 29104289
Graus, F. & Dalmau, J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 16, 535–548 (2019).
pubmed: 30867573
Gill, A. et al. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J. Neuroimmunol. 334, 576980 (2019).
pubmed: 31195181
Haanen, J. et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Ann. Oncol. 31, 724–744 (2020).
pubmed: 32194150
Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra245 (2014).
Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
pubmed: 25840693
Lengacher, C. A. et al. Moderating effects of genetic polymorphisms on improvements in cognitive impairment in breast cancer survivors participating in a 6-week mindfulness-based stress reduction program. Biol. Res. Nurs. 17, 393–404 (2015).
pubmed: 25882604
McGinnis, G. J. & Raber, J. CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy 9, 929–941 (2017).
pubmed: 29338610
pmcid: 6161123
Taraseviciute, A. et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 8, 750–763 (2018).
pubmed: 29563103
pmcid: 6058704
Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739–748 (2018).
pubmed: 29808007
Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126–142.e17 (2020).
pubmed: 32961131
pmcid: 7640763
Chan, E., Fogler, J. M. & Hammerness, P. G. Treatment of attention-deficit/hyperactivity disorder in adolescents: a systematic review. JAMA 315, 1997–2008 (2016).
pubmed: 27163988
Hersey, M. et al. Psychostimulant use disorder, an unmet therapeutic goal: can modafinil narrow the gap? Front. Neurosci. 15, 656475 (2021).
pubmed: 34121988
pmcid: 8187604
Majdi, A., Kamari, F., Sadigh-Eteghad, S. & Gjedde, A. Molecular insights into memory-enhancing metabolites of nicotine in brain: a systematic review. Front. Neurosci. 12, 1002 (2018).
pubmed: 30697142
Bertrand, D. & Terry, A. V. Jr The wonderland of neuronal nicotinic acetylcholine receptors. Biochem. Pharmacol. 151, 214–225 (2018).
pubmed: 29248596
Lower, E. E. et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J. Pain. Symptom Manage 38, 650–662 (2009).
pubmed: 19896571
Mar Fan, H. G. et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support. Care Cancer 16, 577–583 (2008).
pubmed: 17972110
Escalante, C. P. et al. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J. 20, 8–14 (2014).
pubmed: 24445757
pmcid: 4510946
Kohli, S. et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115, 2605–2616 (2009).
pubmed: 19309747
Berenson, J. R. et al. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Support. Care Cancer 23, 1503–1512 (2015).
pubmed: 25370889
Lundorff, L. E., Jønsson, B. H. & Sjøgren, P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat. Med. 23, 731–738 (2009).
pubmed: 19648224
Vega, J. N., Albert, K. M., Mayer, I. A., Taylor, W. D. & Newhouse, P. A. Nicotinic treatment of post-chemotherapy subjective cognitive impairment: a pilot study. J. Cancer Surviv. 13, 673–686 (2019).
pubmed: 31338732
pmcid: 6993088
Miladi, N., Dossa, R., Dogba, M. J., Cléophat-Jolicoeur, M. I. F. & Gagnon, B. Psychostimulants for cancer-related cognitive impairment in adult cancer survivors: a systematic review and meta-analysis. Support. Care Cancer 27, 3717–3727 (2019).
pubmed: 31250183
Stojanoski, B., Wild, C. J., Battista, M. E., Nichols, E. S. & Owen, A. M. Brain training habits are not associated with generalized benefits to cognition: An online study of over 1000 “brain trainers”. J. Exp. Psychol. Gen. 150, 729–738 (2020).
pubmed: 32969685
Simons, D. J. et al. Do “brain-training” programs work? Psychol. Sci. Public Interest. 17, 103–186 (2016).
pubmed: 27697851
Winocur, G., Wojtowicz, J. M., Merkley, C. M. & Tannock, I. F. Environmental enrichment protects against cognitive impairment following chemotherapy in an animal model. Behav. Neurosci. 130, 428–436 (2016).
pubmed: 27337062
Kesler, S. et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin. Breast Cancer 13, 299–306 (2013).
pubmed: 23647804
pmcid: 3726272
Bray, V. J. et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J. Clin. Oncol. 35, 217–225 (2017).
pubmed: 28056205
Poppelreuter, M., Weis, J., Mumm, A., Orth, H. B. & Bartsch, H. H. Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation. Bone Marrow Transpl. 41, 79–90 (2008).
Mayo, S. J. et al. Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study. Pilot. Feasibility Stud. 7, 36 (2021).
pubmed: 33514444
pmcid: 7847007
Dos Santos, M. et al. Cognitive rehabilitation program to improve cognition of cancer patients treated with chemotherapy: a 3-arm randomized trial. Cancer 126, 5328–5336 (2020).
pubmed: 32996583
Nguyen, L., Murphy, K. & Andrews, G. A game a day keeps cognitive decline away? A systematic review and meta-analysis of commercially-available brain training programs in healthy and cognitively impaired older adults. Neuropsychol. Rev. https://doi.org/10.1007/s11065-021-09515-2 (2021). Important review on current (lack of) efficacy evidence for brain training programmes.
doi: 10.1007/s11065-021-09515-2
pubmed: 34398435
Wilson, B. A. Towards a comprehensive model of cognitive rehabilitation. Neuropsychol. Rehabil. 12, 97–110 (2002).
Von Ah, D. & Crouch, A. Cognitive rehabilitation for cognitive dysfunction after cancer and cancer treatment: implications for nursing practice. Semin. Oncol. Nurs. 36, 150977 (2020).
Ferguson, R. J. et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 16, 772–777 (2007). The first investigation into behavioural interventions for cognitive problems after chemotherapy.
pubmed: 17152119
pmcid: 3482484
Abraham, E. H., Khan, B., Ling, E. & Bernstein, L. J. The development and evaluation of a patient educational resource for cancer-related cognitive dysfunction. J. Cancer Educ. https://doi.org/10.1007/s13187-020-01793-3 (2020).
doi: 10.1007/s13187-020-01793-3
Bernstein, L. J., McCreath, G. A., Nyhof-Young, J., Dissanayake, D. & Rich, J. B. A brief psychoeducational intervention improves memory contentment in breast cancer survivors with cognitive concerns: results of a single-arm prospective study. Support. Care Cancer 26, 2851–2859 (2018).
pubmed: 29525841
Cherrier, M. M. et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci. 93, 617–622 (2013).
pubmed: 24012579
Lawrence, J. A. et al. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J. Cancer Surviv. 10, 176–184 (2016).
pubmed: 26130292
Winocur, G. Chemotherapy and cognitive impairment: an animal model approach. Can. J. Exp. Psychol. 71, 265–273 (2017).
pubmed: 29215907
Winocur, G., Binns, M. A. & Tannock, I. Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model. Neuropharmacology 61, 1222–1228 (2011).
pubmed: 21803055
Levy, M. J. F. et al. 5-HTT independent effects of fluoxetine on neuroplasticity. Sci. Rep. 9, 6311 (2019).
pubmed: 31004120
pmcid: 6474908
Mowla, A., Mosavinasab, M. & Pani, A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J. Clin. Psychopharmacol. 27, 67–70 (2007).
pubmed: 17224716
Prado, C. E., Watt, S. & Crowe, S. F. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychol. Rev. 28, 32–72 (2018).
pubmed: 29446012
Kakehi, S. & Tompkins, D. M. A review of pharmacologic neurostimulant use during rehabilitation and recovery after brain injury. Ann. Pharmacother. 55, 1254–1266 (2021).
pubmed: 33435717
Lyons, L., ElBeltagy, M., Bennett, G. & Wigmore, P. Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLoS One 7, e30010 (2012).
pubmed: 22272269
pmcid: 3260195
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01615055?term=NCT01615055&draw=2&rank=1 (2018).
Wang, J. et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 11, 23–35 (2012).
pubmed: 22770240
Ayoub, R. et al. Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nat. Med. 26, 1285–1294 (2020).
pubmed: 32719487
pmcid: 8176964
Hartman, S. J. et al. The effects of weight loss and metformin on cognition among breast cancer survivors: evidence from the Reach for Health study. Psychooncology 28, 1640–1646 (2019).
pubmed: 31140202
pmcid: 6791123
Fabian, C. J., Kimler, B. F. & Hursting, S. D. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Res. 17, 62 (2015).
pubmed: 25936773
pmcid: 4418048
Chang, A. et al. The anti-inflammatory drug aspirin does not protect against chemotherapy-induced memory impairment by paclitaxel in mice. Front. Oncol. 10, 564965 (2020).
pubmed: 33381448
pmcid: 7768078
Pavlock, S., McCarthy, D. M., Kesarwani, A., Jean-Pierre, P. & Bhide, P. G. Hippocampal neuroinflammation following combined exposure to cyclophosphamide and naproxen in ovariectomized mice. Int. J. Neurosci. https://doi.org/10.1080/00207454.2021.1896508 (2021).
doi: 10.1080/00207454.2021.1896508
pubmed: 33635748
Brown, T., Sykes, D. & Allen, A. R. Implications of breast cancer chemotherapy-induced inflammation on the gut, liver, and central nervous system. Biomedicines 9, 189 (2021).
pubmed: 33668580
pmcid: 7917715
Alexander, J. F. et al. Nasal administration of mitochondria reverses chemotherapy-induced cognitive deficits. Theranostics 11, 3109–3130 (2021).
pubmed: 33537077
pmcid: 7847685
Salerno, E. A. et al. Physical activity patterns and relationships with cognitive function in patients with breast cancer before, during, and after chemotherapy in a prospective, nationwide study. J. Clin. Oncol. 39, 3283–3292 (2021).
pubmed: 34406822
Rojer, A. G. M. et al. Objectively assessed physical activity and sedentary behavior and global cognitive function in older adults: a systematic review. Mech. Ageing Dev. 198, 111524 (2021).
pubmed: 34181963
Fernández-Rodríguez, R. et al. Immediate effect of high-intensity exercise on brain-derived neurotrophic factor in healthy young adults: A systematic review and meta-analysis. J. Sport. Health Sci. https://doi.org/10.1016/j.jshs.2021.08.004 (2021).
doi: 10.1016/j.jshs.2021.08.004
pubmed: 34481089
Dauwan, M. et al. Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. J. Neurol. 268, 1222–1246 (2021).
pubmed: 31414194
Kennedy, G., Hardman, R. J., Macpherson, H., Scholey, A. B. & Pipingas, A. How does exercise reduce the rate of age-associated cognitive decline? A review of potential mechanisms. J. Alzheimers Dis. 55, 1–18 (2017).
pubmed: 27636853
Campbell, K. L. et al. The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys. Ther. 100, 523–542 (2020).
pubmed: 32065236
pmcid: 8559683
Rosenberg, A., Mangialasche, F., Ngandu, T., Solomon, A. & Kivipelto, M. Multidomain interventions to prevent cognitive impairment, Alzheimer’s disease, and dementia: from FINGER to World-Wide FINGERS. J. Prev. Alzheimers Dis. 7, 29–36 (2020).
pubmed: 32010923
Kollins, S. H. et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digit. Health 2, e168–e178 (2020).
pubmed: 33334505
Noll, K. R., Bradshaw, M. E., Rexer, J. & Wefel, J. S. Neuropsychological practice in the oncology setting. Arch. Clin. Neuropsychol. 33, 344–353 (2018).
pubmed: 29718081
pmcid: 5920294